APA (7th ed.) Citation

Y, K., K, Y., H, S., T, Y., T, T., S, M., . . . K, M. (2026). Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST). European journal of cancer (Oxford, England : 1990), 238, 116688. https://doi.org/10.1016/j.ejca.2026.116688

Chicago Style (17th ed.) Citation

Y, Kito, et al. "Randomized Phase II Study of FOLFIRI Plus Ramucirumab Versus FOLFOXIRI Plus Ramucirumab as First-line Treatment for Metastatic Colorectal Cancer: WJOG9216G (RECAST)." European Journal of Cancer (Oxford, England : 1990) 238 (2026): 116688. https://doi.org/10.1016/j.ejca.2026.116688.

MLA (9th ed.) Citation

Y, Kito, et al. "Randomized Phase II Study of FOLFIRI Plus Ramucirumab Versus FOLFOXIRI Plus Ramucirumab as First-line Treatment for Metastatic Colorectal Cancer: WJOG9216G (RECAST)." European Journal of Cancer (Oxford, England : 1990), vol. 238, 2026, p. 116688, https://doi.org/10.1016/j.ejca.2026.116688.